Mitochondrial Fusion and Tumor Immunity
CAO Yulu, GAO Song*
Cancer poses a severe threat to public health and imposes a significant burden on families and society. Though immunotherapy has offered curative potential for some patients with advanced cancer, its efficacy in solid tumors remains limited. This limitation is largely attributed to the suppressive effects of the TME (tumor microenvironment) on immune cell vitality and function. Improving the efficacy of immunotherapy for solid tumors has thus become a critical clinical challenge in modern medical research. Mitochondrial fusion is a key event of metabolic regulation and vitality of T cells. This review focuses on perception of enhancing immunotherapeutic effectiveness via promoting mitochondrial fusion.This review focuses on perception of enhancing immunotherapeutic effectiveness via promoting mitochondrial fusion. This paper reviews the molecular mechanisms of mitochondrial fusion mediated by the dynamin superfamily proteins MFN1/2, and how mitochondrial fusion and related organelle dynamics bolster the function of tumor-infiltrating T cells through metabolic regulation and reshaping the immunesuppressive TME. In addition, this review also envisaged the clinical potential for novel immunotherapeutic adjuvant strategies by enhancing T cell mitochondrial function.
CN
EN